Neurothera Labs (TSXV:NTLX) Other Current Receivables: C$0.09 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSXV:NTLX Neurothera Labs Inc TSXV:NTLX
31 GF Score
Price C$0.33
! 2 Warning Signs
View Full Analysis

What is Neurothera Labs Other Current Receivables?

Neurothera Labs TSXV:NTLX +12.07% 31 Other Current Receivables is C$0.09 Mil as of Dec. 2025. GuruFocus rates TSXV:NTLX with a GF Score™ of 31/100. The stock has 2 warning signs investors should review.

Neurothera Labs's Other Current Receivables for the quarter that ended in Dec. 2025 was C$0.09 Mil.

Neurothera Labs's quarterly Other Current Receivables stayed the same from Apr. 2025 (C$0.00 Mil) to Jul. 2025 (C$0.00 Mil) but then increased from Jul. 2025 (C$0.00 Mil) to Dec. 2025 (C$0.09 Mil).

Neurothera Labs Other Current Receivables Related Terms

Neurothera Labs Other Current Receivables Historical Data

* Premium members only.

The historical data trend for Neurothera Labs's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neurothera Labs Other Current Receivables Chart

Neurothera Labs Annual Data
Trend Jan21 Jan22 Jan23 Jan24 Jan25
Other Current Receivables
0.00 0.00 0.00 0.00 0.00

Neurothera Labs Quarterly Data
Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Dec25
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.09
TSXV:NTLX
31GF Score
Neurothera Labs Inc TSXV:NTLX
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Neurothera Labs Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of C$0.09 Mil mean?
Neurothera Labs (TSXV:NTLX) has a Other Current Receivables of C$0.09 Mil as of Dec. 2025. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Neurothera Labs and its competitors.
Is Neurothera Labs' Other Current Receivables too high?
Neurothera Labs' current Other Current Receivables is C$0.09 Mil. Overall, Neurothera Labs has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Neurothera Labs' Other Current Receivables compare to LLY and JNJ?
Neurothera Labs' Other Current Receivables of C$0.09 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Drug Manufacturers company?
A good Other Current Receivables depends on the Drug Manufacturers industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Neurothera Labs and its competitors. Neurothera Labs's current Other Current Receivables is C$0.09 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neurothera Labs stock overvalued right now?
Neurothera Labs (TSXV:NTLX) has a current Other Current Receivables of C$0.09 Mil. The current Other Current Receivables is C$0.09 Mil. Neurothera Labs' overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For Neurothera Labs (TSXV:NTLX), the current Other Current Receivables is C$0.09 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Neurothera Labs Business Description

Address 325 Front Street West, 2nd Floor, Toronto, ON, CAN, M5V2Y1
Neurothera Labs Inc is a specialty clinical-stage pharmaceutical company. The company's focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid therapies. With this focus, it has been engaged in developing and testing pharmaceutical compositions comprised of N-acylethanolamines, CBD and/or other cannabinoid receptors agonists. The Company is currently engaged in development programs based on tetrahydrocannabinol and/or non-psychoactive cannabidiol for the treatment of Tourette syndrome, Alzheimer's disease and agitation, autism spectrum disorder and Status Epilepticus.
31GF Score

Get the complete analysis for TSXV:NTLX

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$0.33
Price